Arena (ARNA)
This is an interesting biopharmaceutical company. It is
focused on developing and commercializing oral drugs that target
G-protein-coupled receptors (GPCRs) in the areas of inflammatory, metabolic,
cardiovascular, and central nervous system.
Presently, they have
studies that involve lorcaserin (BELVIQ) which they have granted Eisai Inc
rights to commercialize in the US and
has been approved by the FDA.
Recently (12/2011), they
have an early stage program for APD811 as an agonist of the prostacyclin
receptor for treatment of pulmonary arterial hypertension.
This company
is interesting because it is using genomic technology and molecular cloning to
identify more novel GPCR genes (also called orphans because the ligands are not
known). Additionally they are using /creating activated receptors of these
receptors to examine what is downstream of the receptor. This way ARENA can
study the receptors without knowning the ligand. Although you would think that
eventually they will determine the ligands, to enhance the relevance of the
receptors function in the body.
ARENA
has several other drugs in the pipeline, but many still a bit in their infancy.
Some of these will be used for multiple
sclerosis, arterial thrombosis and type II diabetes.
Program (Indication)
|
Development Status
|
|
Phase 1
|
||
Preclinical
|
||
Preclinical
|
||
Research
|
What about the stock?
The stock has a recent increase from May at around 2 dollars to 7.28 dollars.
In the last few days it has had some negative pressure, but I think this is a
company to hold for the long run. It has a lot of potential, and it has a
proven technology. Please check out the stock below.
The stock looks like it has
bounced off of the Bollinger bands, so it should start increasing in price if
the Technicals are correct.
(Information compliments of Scottrade and http://www.arenapharm.com/
No comments:
Post a Comment